Althea Technologies, Inc., a leading provider of innovative technologies and services for pharmaceutical development and manufacturing, announced today that it has completed the initial phase of its manufacturing facility expansion. The goal for the expansion project is to satisfy an ever-growing demand for Althea’s aseptic fill/finish, lyophilization, DNA vaccines and protein production services. The project includes expansion of the existing cGMP manufacturing facilities including an overall increase of Althea’s fermentation and purification facilities by 30%, a doubling of early manufacturing suites, allowing for a significant gain in project scheduling and flexibility.
